Thursday, March 06, 2025 12:48:30 PM
JRoon- I get your frustration and can offer no reasoning why the company acts as it does (or does not act when it comes to communications). I look at this stock and value it at zero in my portfolio. My experiences over the years including the few times I have lived through the death of an investment guides me to believe that we are not headed for a good outcome here. I still believe there is a better than 50% chance that I will get above current price for my shares.
I may be incorrect, but I have not seen an instance when Denner has taken a company private. I don't know how that helps him sell V worldwide, and question his desire to get down and dirty and run a small biotech company. The real issue always comes down to what is V worth in its current state and foreseeable future. Only a large organization with marketing resources, R&D budget, sufficient legal budget, and most importantly long time horizon will find any value here. I fail to see compelling reasons why Denner takes the enormous financial risks as well as risks to his reputation in the "activist" space to take on privatizing this tiny one-trick pony of a company. I still believe delisting means nothing to the value we get for our shares. That said, if Amarin is near profitable for the last year, Nasdaq will most certainly grant another 180 day reprieve. Sorry, I can't provide a nice little blurb as to why, just a lot of experience with multiple extensions.
I may be incorrect, but I have not seen an instance when Denner has taken a company private. I don't know how that helps him sell V worldwide, and question his desire to get down and dirty and run a small biotech company. The real issue always comes down to what is V worth in its current state and foreseeable future. Only a large organization with marketing resources, R&D budget, sufficient legal budget, and most importantly long time horizon will find any value here. I fail to see compelling reasons why Denner takes the enormous financial risks as well as risks to his reputation in the "activist" space to take on privatizing this tiny one-trick pony of a company. I still believe delisting means nothing to the value we get for our shares. That said, if Amarin is near profitable for the last year, Nasdaq will most certainly grant another 180 day reprieve. Sorry, I can't provide a nice little blurb as to why, just a lot of experience with multiple extensions.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
